Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphoma.


Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2019
Historique:
pubmed: 25 6 2019
medline: 10 9 2020
entrez: 25 6 2019
Statut: ppublish

Résumé

The large mediastinal mass (LMM) at initial staging represents a risk factor in Hodgkin lymphoma (HL) and is measured by X-ray. Depending on location of the LMM, different results can occur regardless of the initial lymphoma volume. To assess this risk factor more accurately, we evaluated the method of volumetry in 77 patients of HD13/14 study of the German Hodgkin Study Group. Furthermore, volume calculations based on three or only one diameter, were performed to simplify volume assessment. Inter-rater reliability was good for all methods. The 3-diameter measurement produced larger volumes than volumetric assessment with an intraclass correlation coefficient (ICC) of 0.93, which could be improved to 0.95 by multiplying volumes with a correction factor of 0.86. The 1-dimensional measurement strongly overestimated the volume with an ICC of 0.7. In conclusion, the simplified volume estimation based on 3 largest diameters provides a reliable concept for the staging of HL patients.

Identifiants

pubmed: 31232136
doi: 10.1080/10428194.2019.1623888
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3244-3250

Auteurs

Christian Baues (C)

Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany.
German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany.

Helen Görgen (H)

German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany.

Robert Semrau (R)

Radiation Oncology, Bonn-Rhein-Sieg, Siegbur, Germany.

Beatrix Nast-Kolb (B)

Department of Radiooncology, Marienhospital, Düsseldorf, Germany.

Katja Assenmacher (K)

Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany.

Eren Celik (E)

Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany.

Janis Morgenthaler (J)

Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany.

Johannes Rosenbrock (J)

Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany.

Maike Trommer (M)

Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany.

Christian Houbois (C)

Department of Radiology, University Hospital of Cologne, Cologne, Germany.

Carsten Kobe (C)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

Jan Kriz (J)

Department of Radiation Oncology, University Hospital of Muenster, Munster, Germany.

Andreas Engert (A)

German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany.
Department of Internal Medicine and Hematology, University Hospital of Cologne, Cologne, Germany.

Simone Marnitz (S)

Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany.
German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH